Revefenacin - Mylan/Theravance Biopharma

Drug Profile

Revefenacin - Mylan/Theravance Biopharma

Alternative Names: GSK 1160724; TD-4208

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Antiasthmatics; Biphenyl compounds; Carbamates; Piperidines
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Nov 2017 Preregistration for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 01 Nov 2017 Additional efficacy data from a phase III trial in Chronic obstructive pulmonary disease released by Theravance Biopharma
  • 19 Jul 2017 Theravance Biopharma announces intention to submit NDA to US FDA in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top